Analyst Research Report Snapshot

Title:

ARROWHEAD RESEARCH CORP - ARC-520 SET TO BECOME THE KEY DRIVER

Price:

$10.00

Provider:

Edison Investment Research

Date:

17 Apr 2013

Pages:

6

Type:

AcrobatPDF

Companies referenced:

ARWR.OQ

Available for Immediate Download
Summary:

Arrowhead’s investment case is evolving fast with the recent publication of early but impressive data on its anti-hepatitis B agent, ARC-520, in a chimpanzee model of chronic HBV infection. This showed a 90% reduction in hepatitis B antigens (HBeAg) and HBsAg, sufficient to hold out the potential that the agent could become a functional cure. With the initiation of a Phase I safety study of ARC-520 this year and Phase I/II efficacy study next year, Arrowhead is poised to have a major value inflection point once these data become available.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.